A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy

Up to 40% of patients with non-small-cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors (TKIs) present with disease progression in the central nervous system (CNS), either as brain metastases (BM) or leptomeningeal metastases (...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2020-10, Vol.31 (10), p.1397-1404
Hauptverfasser:	Park, S., Lee, M.-H., Seong, M., Kim, S.T., Kang, J.-H., Cho, B.C., Lee, K.H., Cho, E.K., Sun, J.-M., Lee, S.-H., Ahn, J.S., Park, K., Ahn, M.-J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acrylamides Aniline Compounds brain metastases Brain Neoplasms - drug therapy Brain Neoplasms - genetics Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Cohort Studies EGFR T790M ErbB Receptors - genetics Humans leptomeningeal disease Lung Neoplasms - drug therapy Lung Neoplasms - genetics Mutation non-small-cell lung cancer osimertinib Prospective Studies Protein Kinase Inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!